Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dapoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 12/20 | 0.57 |
| ▸ | HTR1D | P28221 | 4/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapoxetine SCHEMBL29387056 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL29488428 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL30600097 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL34479 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL3679561 | 1.00 | HTR1B (0.57) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL29352095 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL119037 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL9292059 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL27937194 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 | |
| Dapoxetine SCHEMBL27518070 | 0.99 | HTR1B (0.56) | HTR1BHTR1DKCNA3KMT2ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | disclosed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | disclosed |
| US-20220315961-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-10-06 | — | — | US | disclosed |
| US-11377673-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11352609-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210301266-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-09-30 | — | — | US | disclosed |
| US-11060072-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10947572-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20130302859-A1 | Engineered imine reductases and methods for the reductive animation of ketone and amine compounds. | CODEXIS,INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302859-A1 | Engineered imine reductases and methods for the reductive animation of ketone and amine compounds. | CODEXIS,INC. (US) | 2013-11-14 | — | — | US | disclosed |
| EP-1671628-B1 | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | APBI HOLDINGS LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-7718705-B1 | administering on an as-needed basis to the mammal a therapeutically effective amount of dapoxetin or salt to a male human to treat sexual dysfunction e.g. premature ejaculation | ELI LILLY AND COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| WO-2008035358-A2 | PROCESS FOR PREPARING DAPOXETINE | CADILA HEALTHCARE LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| EP-1889614-A2 | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | APBI Holdings, LLC (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1671628-A1 | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | APBI Holdings, LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1225881-B1 | THE USE OF DAPOXETINE, A RAPID-ONSET SELECTIVE SEROTONIN REUPTAKE INHIBITOR, FOR TREATING SEXUAL DYSFUNCTION | APBI HOLDINGS LLC (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050261377-A1 | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | APBI HOLDINGS, LLC. | 2005-11-24 | — | — | US | disclosed |
| US-20050215617-A1 | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | APBI HOLDINGS, LLC | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261377-A1 | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | SLC6A4, SLC6A2, HTR5A | SLC6A4 1/4885HTR1B 10/4885HTR1D 18/4885 |
| US-11352609-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | AKR1C4, AKR7A2, AKR1C2 | SLC6A4 3318/4885HTR1B 2552/4885HTR1D 3406/4885 |
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | AKR1C4, AKR7A2, AKR1C2 | SLC6A4 3318/4885HTR1B 2552/4885HTR1D 3406/4885 |
| US-20050215617-A1 | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | SLC6A4, SLC6A2, HTR5A | SLC6A4 1/4885HTR1B 10/4885HTR1D 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.